Rest

What's in it

The combination logic

DSIP is meant to help trigger the deep, restorative stage of sleep specifically, not just make you drowsy. CJC-1295 is added because growth hormone is naturally released most during that same deep-sleep window, so the idea is to support that release rather than work against it. BPC-157 rounds it out with general tissue support, so the overnight window is being used for repair as well as rest. Clinical detail: DSIP (delta sleep-inducing peptide) enhances slow-wave sleep and modulates the hypothalamus to balance hormonal rhythms, including normalizing cortisol, without acting as a classic sedative. CJC-1295 is a GHRH analog that, when timed to the sleep window, is proposed to amplify the endogenous nocturnal GH pulse that occurs naturally during slow-wave sleep. BPC-157 contributes broad cytoprotective and tissue-repair signaling via growth-hormone receptor upregulation and VEGFR2-Akt-eNOS pathway modulation. The three are proposed to work on complementary, non-competing timescales within the same overnight recovery window.

Is there evidence for the combination, or only for the parts? DSIP has decades of laboratory research behind its proposed sleep-architecture effects but limited modern human trial data. CJC-1295 and BPC-157 each have their own separate evidence bases (discussed on their individual pages) but neither was studied specifically for sleep-timed administration. No study has tested this three-peptide sleep-timed combination directly — the rationale is built from each component’s individual mechanism, not from combination-specific research.

What it's used for

Overlaps & stacked risks

• Combining three active peptides carries the summed risk profile of all three, not a reduced one.
• DSIP should specifically be avoided in patients with epilepsy or severe psychiatric conditions.
• BPC-157’s tissue-growth-supporting mechanism is a theoretical concern in patients with any active or undiagnosed abnormal growth.
• Vivid dreams, mild grogginess, or headache have been reported with DSIP individually.

Who it is not for

• Pregnant or breastfeeding patients
• Patients with epilepsy or a severe psychiatric disorder — DSIP specifically should be avoided in these groups without provider oversight
• Anyone with a personal or family history of cancer, without physician clearance, given BPC-157’s role in tissue growth signaling
• Competitive athletes subject to anti-doping testing — CJC-1295 is prohibited in-competition

Who it suits

Patients with disrupted sleep architecture or insufficient deep sleep who have no seizure or psychiatric history contraindicating DSIP, and who have discussed the individual (not combination-specific) evidence for each component with their provider.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine — but it is the difference between a licensed pharmacy working to a standard and an unregulated website. This page describes Rest for general educational purposes. It is not medical advice and does not replace a consultation with a licensed provider. Individual results vary, and combination products carry the risks of each included peptide.